Eirini Katodritou

6.0k total citations
108 papers, 2.5k citations indexed

About

Eirini Katodritou is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Eirini Katodritou has authored 108 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Hematology, 56 papers in Oncology and 43 papers in Molecular Biology. Recurrent topics in Eirini Katodritou's work include Multiple Myeloma Research and Treatments (79 papers), Peptidase Inhibition and Analysis (27 papers) and Protein Degradation and Inhibitors (23 papers). Eirini Katodritou is often cited by papers focused on Multiple Myeloma Research and Treatments (79 papers), Peptidase Inhibition and Analysis (27 papers) and Protein Degradation and Inhibitors (23 papers). Eirini Katodritou collaborates with scholars based in Greece, United States and Italy. Eirini Katodritou's co-authors include Evangelos Terpos, Meletios Α. Dimopoulos, Konstantinos Zervas, Anastasia Pouli, Evgenia Verrou, Efstathios Kastritis, Argiris Symeonidis, Eurydiki Michalis, Kostas Zervas and Sosana Delimpasi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eirini Katodritou

99 papers receiving 2.4k citations

Peers

Countries citing papers authored by Eirini Katodritou

Since Specialization

Citations

This map shows the geographic impact of Eirini Katodritou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eirini Katodritou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eirini Katodritou more than expected).

Fields of papers citing papers by Eirini Katodritou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eirini Katodritou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eirini Katodritou. The network helps show where Eirini Katodritou may publish in the future.

Co-authorship network of co-authors of Eirini Katodritou

This figure shows the co-authorship network connecting the top 25 collaborators of Eirini Katodritou. A scholar is included among the top collaborators of Eirini Katodritou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eirini Katodritou. Eirini Katodritou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies 2025 ·HemaSphere ·Eirini Katodritou, Evangelos Terpos	0
2	Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, (unknown), (unknown), (unknown), (unknown), Emmanouil Spanoudakis, (unknown), Michalis Michael, Stavroula Giannouli, Georgia Kaiafa, Eirini Katodritou, Evangelos Terpos, Meletios Α. Dimopoulos, Efstathios Kastritis	0
3	Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management 2025 ·American Journal of Hematology ·Eirini Katodritou, Evangelos Terpos, Suzanne Lentzsch, Shaji Kumar	1
4	Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis 2025 ·American Journal of Hematology ·Joshua Richter, Ajay K. Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, (unknown), (unknown), Leanne Cooper, (unknown), Nick Ballew, (unknown), Natalie Boytsov, (unknown), Simon McNamara	1
5	Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review 2024 ·Life ·(unknown), (unknown), (unknown), (unknown), (unknown), Eirini Katodritou, (unknown)	4
6	Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG) 2024 ·Leukemia & lymphoma ·Efstathios Kastritis, Eirini Katodritou, Sorina Bădeliță, Jelena Bila, Güldane Cengiz Seval, Zorica Cvetković, Daniel Coriu, Emmanouil Spanoudakis, (unknown), (unknown), (unknown), Anca Bojan, Milena Mitrović, (unknown), Maria Gavriatopoulou, Μαρία Ρούσσου, (unknown), Evangelos Terpos, Meral Beksac, Meletios A. Dimopoulos	1
7	Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA 2024 ·American Journal of Hematology ·Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Panagiotis Malandrakis, Evgenia Verrou, (unknown), Magdalini Migkou, Kyriaki Manousou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios Α. Dimopoulos	10
8	P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG) 2023 ·HemaSphere ·Efstathios Kastritis, Eirini Katodritou, Sorina Bădeliță, Jelena Bila, Güldane Cengiz Seval, Zorica Cvetković, Daniel Coriu, Emmanouil Spanoudakis, (unknown), (unknown), (unknown), Anca Bojan, Milena Mitrović, (unknown), Maria Gavriatopoulou, Μαρία Ρούσσου, Meletios Α. Dimopoulos, Meral Beksaç, Evangelos Terpos	1
9	Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications 2022 ·American Journal of Hematology ·Efstathios Kastritis, Magdalini Migkou, (unknown), Maria Gavriatopoulou, Despina Fotiou, Μαρία Ρούσσου, Nikolaos Kanellias, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Foteini Theodorakakou, (unknown), Evangelos Eleutherakis‐Papaiakovou, (unknown), Evangelos Terpos, Eirini Katodritou, Meletios Α. Dimopoulos	21
10	Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe 2022 ·Cancers ·Evangelos Terpos, Renato Zambello, Xavier Leleu, (unknown), Sorina Bădeliță, Eirini Katodritou, (unknown), (unknown), Sally Wetten, Jo Caers	5
11	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls 2022 ·Journal of Clinical Medicine ·Eleni Gavriilaki, (unknown), Foteini Theodorakakou, Christine‐Ivy Liacos, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Evgenia Verrou, (unknown), (unknown), (unknown), Tasoula Touloumenidou, (unknown), Apostolia Papalexandri, Ioanna Sakellari, Meletios Α. Dimopoulos, Efstathios Kastritis, Eirini Katodritou	8
12	Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel 2022 ·SHILAP Revista de lepidopterología ·Xavier Leleu, Eirini Katodritou, (unknown), Evangelos Terpos, Jo Caers, Renato Zambello, (unknown), (unknown), Sally Wetten, Sorina Bădeliță	5
13	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group 2021 ·Journal of Clinical Medicine ·Jelena Bila, Eirini Katodritou, (unknown), Sandra Bašić‐Kinda, Daniel Coriu, (unknown), (unknown), (unknown), (unknown), Samo Zver, Meral Beksaç, Evangelos Terpos, Meletios Α. Dimopoulos	12
14	Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment 2021 ·Journal of Clinical Medicine ·(unknown), Eirini Katodritou	18
15	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial 2020 ·Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial, (unknown)	53
16	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study 2020 ·Leukemia Research ·(unknown), Moshe E. Gatt, Adir Shaulov, Eirini Katodritou, (unknown), Noa Lavi, Anastasia Pouli, (unknown), Iuliana Vaxman, Miri Zektser, Chezi Ganzel, Noam Benyamini, Svetlana Trestman, Tomer Ziv‐Baran, Yasmin Adam, Yaël C. Cohen, Irit Avivi	2
17	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study) 2019 ·Blood ·(unknown), Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michèle Cavo, Elena Zamagni, Eirini Katodritou, Barbara Gamberi, Marie‐Christine Kyrtsonis, Maria Gavriatopoulou, Μαρία Ρούσσου, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Meletios Α. Dimopoulos	0
18	Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome 2019 ·Annals of Hematology ·(unknown), (unknown), Evangelos Terpos, E. Yiannaki, Dimitra Markala, (unknown), Αθανάσιος Παπαθεοδώρου, (unknown), Evgenia Verrou, (unknown), Pavlina Konstantinidou, Eirini Katodritou	15
19	The Management and Costs of Multiple Myeloma in Greece: Mapping the Local Treatment Pathway and Associated Resource Use 2016 ·Value in Health ·Όλγα Σίσκου, (unknown), Sosana Delimpasi, Eirini Katodritou, (unknown), Anastasia Pouli, Panagiotis Repousis, Evangelos Terpos, (unknown), (unknown), Olympia Konstantakopoulou, Ilias Goranitis, (unknown), Meletios Α. Dimopoulos	0
20	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration 2009 ·Haematologica ·Evangelos Terpos, Eirini Katodritou, (unknown), Efstathios Kastritis, D. Christoulas, Anastasia Pouli, Eurydiki Michalis, (unknown), Konstantinos Anargyrou, Konstantinos Tsionos, Meletios Α. Dimopoulos, Konstantinos Zervas	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact